Long-term oral anticoagulant (OAC) therapy is used for the treatment and prevention of
thrombosis and thromboembolism. As OAC use is so widespread, emergency physicians …

Thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban, apixaban and edoxaban
form a new class of non-vitamin K antagonist oral anticoagulants and have been extensively …

Clinicians prescribing new oral anticoagulants (OACs; dabigatran, rivaroxaban, and
apixaban) should be aware of the exclusion criteria related to bleeding risks defined in …

Background and Purpose—In patients receiving direct oral anticoagulants (DOACs),
emergency treatment like thrombolysis for acute ischemic stroke is complicated by …

Direct oral anticoagulants (DOACs) exert similar anticoagulant effects to vitamin K
antagonists and are increasingly used worldwide. Nevertheless, an evidence-based …

Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

A new generation of antithrombotic agents has recently emerged. These provide direct
inhibition of either thrombin (factor IIa [FIIa]) or FXa, and are increasingly replacing the …

The direct acting oral anticoagulants (DOAC s), including dabigatran, rivaroxaban,
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …

Dabigatran, apixaban, and rivaroxaban have been approved for primary and secondary
stroke prevention in patients with atrial fibrillation. However, questions have arisen about …

Although the direct oral anticoagulants (DOACs) do not require routine monitoring and
reduce bleeding compared with warfarin, there are special circumstances in which …